Editors wanted
Why Deerfield picked Editas for its first gene editing investment
Deerfield Management has made an initial $20 million bet on CRISPR technology with Editas Medicine, but other gene editing companies shouldn't assume the firm is closed for business.
The firm's investment was part of Editas' $120 million series B round last week that was led by bng0, which represents multiple family offices including those of Bill Gates and was formed solely to invest in Editas. The round also included Viking Global Investors, Fidelity Management & Research, funds and accounts managed by T. Rowe Price, Google Ventures, Jennison Associates, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments; Alexandria Venture Investments, Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund...